A turning point for pancreatic cancer patients

Eli Lilly announces two China deals, Akeso's lung cancer bispecific payoff, and more biotech news from The Readout Cancer ASCO FDA Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT@ASCO Search Log In Try STAT+ My Account Home Newsletter The Readout A turning point for pancreatic cancer patients Eli Lilly announces two China deals, Akeso’s lung cancer…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

We’re catching up on plenty of ASCO news from over the weekend, including detailed daraxonrasib results in pancreatic cancer, and a Chinese lung cancer therapy that continues to outperform expectations.

Also, a decades-old peptide beloved by biohackers has become a lightning rod in a battle over FDA regulation of these substances.

Continue to STAT+ to read the full story…